Effects of Changjishu soft elastic capsule in treatment of diarrhea-predominant irritable bowel patients with liver-qi stagnation and spleen deficiency syndrome: A randomized double-blinded controlled trial

Journal of Chinese Integrative Medicine

Volumn 7, Issue 3, 2009, Pages 212-217

  Gao, Wen Yan ^a   Lin, Yi Fan ^a   Chen, Shan Quan ^a   Lu, Yu Ping ^a   Yang, Zhuo ^a   Gong, Yang ^a   Liu, Yang ^a   Wang, Li Xin ^a   Wang, Chang Hong ^a  

^a GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Changjishu soft elastic capsule; Irritable bowel syndrome; Liver qi stagnation; Safety; Spleen deficiency; Treatment outcome

Indexed keywords

CHANGJISHU; CHINESE DRUG; GLUTAMINE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CHINESE MEDICINE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEFECATION HABIT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENTERIC COATED TABLET; FECES COMPOSITION; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; SPLEEN DISEASE;

ADOLESCENT; ADULT; AGED; CAPSULES; DIAGNOSIS, DIFFERENTIAL; DIARRHEA; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PHYTOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 68949104006     PISSN: 16721977     EISSN: None     Source Type: Journal    
DOI: 10.3736/jcim20090303     Document Type: Article

References (14)

1. Duan N, Lin SR. Evaluation and progress of drug treatment for digestive diseases: the memoir of experts round table conference on rational use of drug for digestive diseases. Zhongguo Yi Yuan Yong Yao Ping Jia Yu Fen Xi. 2008; 8(8): 561-564.
2. Clinical Services Committee of the British Society of Gastroenterology. New guidelines for diagnosis and treatment of adult irritable bowel syndrome. Xian Dai Xiao Hua Ji Jie Ru Zhen Lian. 2007; 12 (2): 141.
3. Friedel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology. 2001; 120(2): 557-560.
4. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol. 2003; 98(5): 1117-1122.
5. Branch Association for Diseases of Digestive System, Chinese Medical Association. A consensus view of the diagnosis and treatment of irritable bowel syndrome. Zhonghua Xiao Hua Za Zhi. 2003; 23(7): 724.
6. Zheng XY. Guidelines for clinical research on Chinese new herbal medicines (trial implementation). Beijing: China Medical Pharmaceutical Science & Technology Publishion House. 2002: 139-143, 364-366.
7. State Food and Drug Administration. Technical requirements of research on Chinese new herbal medicines. 1999: 34-37.
8. Xu XY, Wang AY, Wang DH, Wang DN. Efficacy of glutamine compound in treatment of diarrhea-predominant irritable bowel syndrome. Zhongguo Yi Shi Jin Xiu Za Zhi. 2003; 30 (6): 17-18.
9. Su H, Sheng JQ, Chen ZM, Li AQ, Yan W, Yu DL, Zhang YH, Li SR. Clinical efficacy of glutamine compound enteric capsules in the treatment of diarrhea-predominant irritable bowel syndrome. Wei Chang Bing Xue Za Zhi. 2006; 11(10): 602-604.
10. Naliboff BD, Chang L, Munakata J, Mayer EA. Towards an integrative model of irritable bowel syndrome. Prog Brain Res. 2000; 122: 413-423.
11. Wang WA, Qian JM, Pan GZ. Pathogenesis of irritable bowel syndrome. Wei Chang Bing Xue He Gao Bing Xue Za Zhi. 2001; 10(2): 99-102.
12. Chen WX, Shi ZP, Dou YR, Lu Y. Effects of modified Tongxieyaofang Decoction on isolated colon of irritable bowel syndrome. Zhong Yao Yao Li Yu Lin Chuang. 2008; 24(3): 3-4.
13. Sun X, Cai G, Wang WJ. Observation on intestinal flora in patients of irritable bowel syndrome after treatment of Chinese integrative medicine. J Chin Integr Med. 2004; 2(5): 340-342.
14. Corazziari E, Bytzer P, Delvaux M, Holtmann G, Malagelada JR, Morris J, Muller-Lissner S, Spiller RC, Tack J, Whorwell PJ. Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 18(6): 569-580.